Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3693-3700

  Lin, Cheng Jui ^a,b   Wu, Chih Jen ^a,b,c   Pan, Chi Feng ^a,b   Chen, Yi Chou ^a   Sun, Fang Ju ^a,b   Chen, Han Hsiang ^a,b  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Haemodialysis; Indoxyl sulphate; P cresol; P cresyl sulphate; Protein bound uraemic toxin

Indexed keywords

C REACTIVE PROTEIN; INDICAN; PARA CRESOL; 4-CRESOL; CRESOL; PLASMA PROTEIN;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BACTEREMIA; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CELLULITIS; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFECTIOUS DIARRHEA; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINARY TRACT INFECTION; BLOOD; KIDNEY PLASMA FLOW; METABOLISM; MIDDLE AGED; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; C-REACTIVE PROTEIN; CRESOLS; FEMALE; HUMANS; INDICAN; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL PLASMA FLOW;

EID: 79952200542     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq251     Document Type: Article

References (29)

1. Zimmermann J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658 (Pubitemid 29082891)
2. Descamps-Latscha B. The immune system in end-stage renal disease. Curr Opin Nephrol hypertens 1993; 2: 883-891
3. Shurtz-Swirski R, Shkolnik T, Shasha SM. Parathyroid hormone cupro and the cellular immune system. Nephron 1995; 70: 21-24
4. Bradley JR, Johnson DR, Pober JS. Four different classes of inhibitors of receptor-mediated endocytosis decrease tumor necrosis factorinduced gene expression in human endothelial cells. J Immunol 1993; 150: 5544-5555 (Pubitemid 23180669)
5. Vanholder R, De Smet R,Waterloos MA et al. Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 1995; 47: 510-517
6. Wratten ML, Tetta C, De Smet R et al. Uremic ultrafiltrate inhibits platelet-Activating factor synthesis. Blood Purif 1999; 17: 134-141 (Pubitemid 29403571)
7. Martinez AW, Recht NS, Hostetter TH et al. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005; 16: 3430-3436 (Pubitemid 46187553)
8. De Loor H, Bammens B, Evenepoel P et al. Gas chromatographic- mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51: 1535-1538 (Pubitemid 41060897)
9. Schepers E, Meert N, Glorieux G et al. p-Cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596 (Pubitemid 46189906)
10. Bammens B, Evenepoel P, Keuleers H et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087 (Pubitemid 43372184)
11. Meijers BK, Bammens B, De Moor B et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-1180 (Pubitemid 351620433)
12. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96-104 (Pubitemid 2125685)
13. Niwa T, Nomura T, Sugiyama S et al. The protein metabolite hypothesis, a model for the progression of renal failure: An oral sorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997; 52: S23-S28 (Pubitemid 27489396)
14. Dou L, Bertrand E, Cerini C et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451 (Pubitemid 38130638)
15. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007; 27: 30-35 (Pubitemid 46364538)
16. Daugirdas JT. The post:pre-dialysis plasma urea nitrogen ratio to estimate Kt/V and nPCR: Mathematical modeling. Int J Artif Organs 1989; 12: 411-419 (Pubitemid 19185306)
17. Hotchkiss RS, Pugin J. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 120: 138
18. Eknoyan G, Beck GJ, Cheung AK et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. New Engl J Med 2002; 347: 2010-2019 (Pubitemid 35461657)
19. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320 (Pubitemid 34441412)
20. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943 (Pubitemid 36513344)
21. Liabeuf S, Barreto DV, Barreto FC et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183-1191
22. Dou L, Cerini C, Brunet P et al. p-Cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002; 62: 1999-2009 (Pubitemid 35366154)
23. Miki S, Shinichi K, Kumi O et al. Prediction of infectious events by high-sensitivity C-reactive protein level before undergoing chemotherapy for acute myeloid leukaemia. Scand J Infect Dis 2010; 42: 97-101
24. Arber C, Passweg JR, Fluckiger U et al. C-reactive protein and fever in neutropenic patients. Scand J Infect Dis 2000; 32: 515-520
25. De Smet R, Van Kaer J, Van Vlem B et al. The toxicity of the free non-protein bound fraction of p-cresol: A prospective and crosssectional analysis. Clin Chem 2003; 49: 470-478 (Pubitemid 36250208)
26. Shemin D, Bostom A, Laliberty P et al. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38: 85-90 (Pubitemid 32611763)
27. Shemin D, Bostom AG, Lambert C et al. Residual renal function in a large cohort of peritoneal dialysis patients: Change over time, impact on mortality and nutrition. Perit Dial Int 2000; 20: 439-444
28. Bammens B, Evenepoel P, Verbeke K et al. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 2005; 46: 512-519 (Pubitemid 41208188)
29. Bammens B, Evenepoel P, Verbeke K et al. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64: 2238-2243 (Pubitemid 37449560)